Table 1 Characteristics of the Rivaroxaban and Warfarin Intent-To-Treat Cohorts After IPTW
RivaroxabanN = 2097% | WarfarinN = 2842% | Absolute Standardized Difference | |
|---|---|---|---|
Demographics | |||
Age, median (25, 75% range) | 50 (39, 62) | 51 (40, 64) | – |
Age 18–49 years | 45.5 | 43.6 | 0.04 |
Age 50–64 years | 29.6 | 29.2 | 0.01 |
Age 65–74 years | 13.1 | 13.7 | 0.02 |
Age 75–79 years | 4.3 | 4.7 | 0.02 |
Age ≥ 80 years | 7.5 | 8.9 | 0.05 |
Female sex | 56.4 | 56.4 | 0.00 |
Pulmonary embolism (±deep vein thrombosis) | 18.6 | 19.1 | 0.01 |
Comorbidities | |||
Chronic obstructive pulmonary disease | 8.6 | 9.6 | 0.04 |
Asthma | 13.1 | 13.6 | 0.02 |
Heart Failure | 5.1 | 5.4 | 0.01 |
Hypertension | 53.5 | 55.2 | 0.03 |
Ischemic stroke | 3.6 | 4.3 | 0.04 |
Diabetes | 22.3 | 23.0 | 0.02 |
Dementia | 2.6 | 3.3 | 0.04 |
Coronary artery disease | 0.8 | 0.7 | 0.01 |
Carotid stenosis | 0.6 | 0.8 | 0.03 |
Peripheral vascular disease | 5.5 | 5.8 | 0.01 |
Myocardial infarction | 5.2 | 5.9 | 0.03 |
Percutaneous coronary intervention | 3.5 | 4.1 | 0.03 |
Coronary artery bypass grafting | 2.4 | 2.8 | 0.02 |
Gastrointestinal bleed | 0.3 | 0.5 | 0.02 |
Intracranial hemorrhage | 0.0 | 0.3 | 0.07 |
Acute kidney injury | 11.0 | 12.5 | 0.05 |
Other kidney injury | 0.3 | 0.5 | 0.04 |
Inflammatory bowel disease | 1.2 | 1.6 | 0.04 |
eGFR > 90 mL/minute | 53.6 | 51.7 | 0.04 |
eGFR 60–89 mL/minute | 30.9 | 30.8 | 0.00 |
eGFR 30-59 mL/minute | 11.1 | 11.3 | 0.01 |
eGFR 15–29 mL/minute | 1.9 | 2.7 | 0.06 |
eGFR < 15 mL/minute | 1.7 | 2.6 | 0.06 |
eGFR unknown | 0.7 | 0.7 | 0.01 |
Liver disease | 1.6 | 1.6 | 0.00 |
Coagulopathy | 3.1 | 3.5 | 0.02 |
Gastroesophageal reflux disease | 18.9 | 18.8 | 0.00 |
Anemia | 25.5 | 27.7 | 0.05 |
Sleep apnea | 10.4 | 10.2 | 0.01 |
Smoking | 27.4 | 27.4 | 0.00 |
Hemorrhoids | 2.3 | 2.6 | 0.02 |
Alcohol abuse | 0.4 | 0.3 | 0.02 |
Anxiety | 12.6 | 12.2 | 0.01 |
Depression | 1.6 | 1.8 | 0.02 |
Psychosis | 1.5 | 1.5 | 0.00 |
BMI < 18.5 kg/m2 | 1.9 | 1.9 | 0.00 |
BMI 18.5–24.9 kg/m2 | 15.8 | 16.5 | 0.02 |
BMI 25.0–29.9 kg/m2 | 24.8 | 24.6 | 0.01 |
BMI 30.0–34.9 kg/m2 | 23.0 | 23.0 | 0.00 |
BMI 35.0–39.9 kg/m2 | 14.7 | 14.3 | 0.01 |
BMI ≥40 kg/m2 | 18.4 | 18.4 | 0.00 |
BMI < 18.5 kg/m2 | 1.3 | 1.2 | 0.01 |
Rheumatoid arthritis | 6.2 | 5.8 | 0.02 |
Osteoarthritis | 18.9 | 19.9 | 0.03 |
Headache | 10.7 | 11.1 | 0.01 |
Diverticulitis | 3.8 | 3.8 | 0.00 |
H. pylori treatment | 0.4 | 0.6 | 0.02 |
Hypothyroidism | 0.8 | 0.9 | 0.00 |
Solid tumor | 9.5 | 10.2 | 0.02 |
Metastatic cancer | 3.5 | 3.8 | 0.01 |
Major surgery | 9.8 | 9.7 | 0.01 |
Varicose veins | 1.4 | 1.3 | 0.01 |
Comedications | |||
Aspirin | 22.7 | 24.0 | 0.03 |
P2Y12 platelet inhibitor | 3.1 | 4.0 | 0.05 |
Nonsteroidal anti-inflammatory drug | 31.8 | 30.8 | 0.02 |
Celecoxib | 1.1 | 1.0 | 0.01 |
Angiotensin-converting enzyme inhibitor or receptor blocker | 31.1 | 32.2 | 0.02 |
Beta-blocker | 23.5 | 25.3 | 0.04 |
Diltiazem | 1.8 | 2.0 | 0.01 |
Verapamil | 0.9 | 1.1 | 0.02 |
Dihydropyridine calcium channel blocker | 21.2 | 21.8 | 0.01 |
Loop diuretic | 11.0 | 11.9 | 0.03 |
Thiazide | 21.2 | 21.4 | 0.00 |
Digoxin | 0.5 | 0.8 | 0.04 |
Statin | 23.7 | 24.5 | 0.02 |
Other cholesterol medication | 2.0 | 2.1 | 0.01 |
Metformin | 11.7 | 11.5 | 0.01 |
Sulfonylurea or glinides | 5.1 | 6.0 | 0.04 |
Thiazolidinediones | 0.5 | 0.6 | 0.02 |
Dipeptidyl peptidase 4 inhibitors | 1.5 | 1.4 | 0.01 |
Glucagon-like peptide-1 agonist | 0.5 | 0.3 | 0.03 |
Insulin | 7.8 | 8.9 | 0.04 |
Selective serotonin reuptake or serotonin-norepinephrine reuptake inhibitor | 10.6 | 11.3 | 0.02 |
Other antidepressants | 9.0 | 9.7 | 0.03 |
Proton pump inhibitors | 21.4 | 22.6 | 0.03 |
Histamin-2 receptor antagonist | 8.4 | 9.0 | 0.02 |
Systemic corticosteroids | 17.8 | 18.8 | 0.03 |
Alpha-glucosidase inhibitor | 0.1 | 0.0 | 0.04 |
Hypnotic medication | 3.7 | 3.6 | 0.00 |
Sodium-glucose cotransporter-2 inhibitor | 0.3 | 0.2 | 0.02 |